Abstracts tagged "juvenile myositis"

Abstract Number: 049 • 2023 Pediatric Rheumatology Symposium
What Happens After Juvenile Myositis Patients Screen Positive for Mental Health Comorbidities? Update from a Multicenter Juvenile Myositis Mental Health Screening Pilot Study
Kaveh Ardalan¹, Rebecca Fillipo¹, Christina ZIgler², Audrey Ward¹, Jeffrey Dvergsten³, Ann Reed¹, Alison Manning¹, Gary Maslow¹, Brian Feldman⁴, Ashley Danguecan⁵, Sarah Mossad⁵, Luana Flores Pereira⁵, Susan Shenoi⁶, Stacey Haynes⁷, Joanna Patten⁷ and Andrea Knight⁵, ¹Duke University School of Medicine, Durham, NC, ²Duke, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Hospital for Sick Children / University of Toronto, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Seattle Children's Hospital, Seattle, WA, ⁷Seattle Childrens Hospital and Research Center / University of Washington, Seattle, WA
Background/Purpose: Juvenile myositis (JM) patients report high rates of emotional distress but qualitative studies suggest challenges accessing high quality mental health care. We present survey…
Abstract Number: 120 • 2020 Pediatric Rheumatology Symposium
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
Jessica Neely¹, Adam Huber ² and Susan Kim ³ for the CARRA investigators, ¹University of California, San Francisco, San Francisco, California, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³University of California, San Francisco, San Francisco
Background/Purpose: The New CARRA Registry of Juvenile Myositis (JM) was developed in 2017 to collect 10-year longitudinal data to increase knowledge of the course of…
Abstract Number: 125 • 2020 Pediatric Rheumatology Symposium
Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis
Kaveh Ardalan¹, Alison Manning ¹, Brian Feldman ², Gary Maslow ¹ and Andrea Knight ³, ¹Duke University Medical Center, Durham, ²The Hospital for Sick Children, Toronto, Canada, ³SickKids Research Institute, Toronto, Canada
Background/Purpose: Juvenile myositis (JM) negatively affects health-related quality of life due to chronic weakness, skin/muscle damage, multiorgan dysfunction, and side effects of immunosuppression. While JM’s…
Abstract Number: 433 • 2019 ACR/ARP Annual Meeting
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Ruchi Patel ¹, Valeria Esparza ², Jin-Shei Lai ¹, Elizabeth Gray ¹, Rowland Chang ³, David Cella ³ and Kaveh Ardalan⁴, ¹Northwestern University Feinberg School of Medicine, Chicago, ²University of Illinois-Chicago College of Medicine, Chicago, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Background/Purpose: Compared to healthy children, youth with juvenile myositis (JM) often report poorer health-related quality of life (HRQoL). Legacy HRQoL measures may underestimate the impact…
Abstract Number: 775 • 2019 ACR/ARP Annual Meeting
Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin
Jessica Turnier¹, Celine Berthier ¹, Lam Tsoi ¹, Lori Lowe ¹, Gabrielle Morgan ², Johann Gudjonsson ¹, Lauren Pachman ² and J. Michelle Kahlenberg ¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago
Background/Purpose: Skin inflammation can herald systemic disease manifestations and disease chronicity in juvenile myositis (JM), yet we lack an understanding of the pathogenic mechanisms driving…
Abstract Number: 2241 • 2019 ACR/ARP Annual Meeting
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Kaveh Ardalan¹, Oluwatosin Adeyemi ², Dawn Wahezi ³, Anne Caliendo ⁴, Megan L. Curran ⁵, Jessica Neely ⁶, Susan Kim ⁶, Colleen Correll ⁷, Emily Brunner ⁸ and Andrea Knight ⁹, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, ²Children's Hospital of Philadelphia, Philadelphia, ³Children’s Hospital at Montefiore, New York, ⁴Northwestern University Feinberg School of Medicine, Chicago, ⁵University of Colorado, Aurora, CO, ⁶University of California, San Francisco, San Francisco, CA, ⁷University of Minnesota, Minneapolis, ⁸Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: While juvenile myositis (JM) can negatively affect quality of life, studies of the emotional health needs of youth with JM are limited. We examined…
Abstract Number: 481 • 2018 ACR/ARHP Annual Meeting
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
Emily Brunner¹, Laura Tasan², Kathryn S. Torok³, Bonny Rockette-Wagner⁴, Christina K. Zigler⁵, Kaila Schollaert-Fitch³, Diane Koontz⁶, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ⁶Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…
Abstract Number: 90 • 2017 Pediatric Rheumatology Symposium
Risk of Serious Infections in Juvenile Dermatomyositis patients treated with biological response modifiers including rituximab and abatacept
Sukesh Sukumaran¹ and Vini Vijayan², ¹ACH, UAMS, Little Rock, AR, ²Pediatrics, UAMS, Little Rock, AR
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic auto immune disease in children. The risk of infection is increased with immunomodulation. There are no studies…
Abstract Number: 1365 • 2016 ACR/ARHP Annual Meeting
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, Nastaran Bayat², Michael Ward³, Adam Huber⁴, Lan Wu¹, Gulnara Mamyrova⁵, Ira Targoff⁶, William Warren-Hicks⁷, Frederick W. Miller², Lisa G. Rider⁸ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴IWK Health Centre, Halifax, NS, Canada, ⁵Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁶VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Social and Scientific Systems, Inc., Durham, NC, ⁸Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with characteristic rashes and chronic muscle inflammation. Because of its rarity, most therapeutic choices are based…
Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting
Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies
Adam M. Huber¹, Gulnara Mamyrova², Julia A. Lee³, Peter A. Lachenbruch⁴, Ira N. Targoff⁵, Frederick W. Miller⁴, Lisa G. Rider⁴ and Childhood Myositis Heterogeneity Study Group⁶, ¹Dalhousie University, Halifax, NS, Canada, ²Rheumatology, George Washington University, Washington, DC, ³Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
Abstract Number: 282 • 2012 ACR/ARHP Annual Meeting
Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children
Gulnara Mamyrova¹, James D. Katz¹, Robert V. Jones², Peter A. Lachenbruch³, Mona Shah³, Olcay Y. Jones¹, Anupam Chahal¹, Seema Agrawal¹, Frederick W. Miller³, Lisa G. Rider³ and the Childhood Myositis Heterogeneity Group⁴, ¹Rheumatology, George Washington University, Washington, DC, ²Pathology, George Washington University, Washington, DC, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Niehs, NIH, Bethesda, MD
Background/Purpose: We examined demographic, clinical and laboratory features of juvenile polymyositis (JPM) and muscular dystrophy in children to improve classification of these two conditions. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].